Bull case
Sutro Biopharma is compelling because its lead asset STRO-004 is showing early confirmed and unconfirmed partial responses across multiple solid tumors, including PDAC, HNSCC, and NSCLC, while dose optimization is underway in 49 heavily pre-treated patients, suggesting meaningful clinical potential despite no near-term revenue or earnings. The thesis is further strengthened by a differentiated TF ADC design—Fc-silent backbone, stabilized linker, DAR8 exatecan payload, and low observed neutropenia—that appears to address historical tissue factor ADC liabilities such as ocular toxicity, neuropathy, and bleeding risk. Financially, Sutro’s $202.6M cash balance at 1Q26 and funding into at least 2Q28, alongside lower R&D and G&A spending and a narrowed net loss of $38.5M, support an increasingly de-risked platform story with multiple programs advancing.